A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder

Journal of Clinical Psychiatry

Volumn 64, Issue 6, 2003, Pages 640-647

  Hollander, Eric ^a   Koran, Lorrin M ^b   Goodman, Wayne K ^c   Greist, John H ^d   Ninan, Philip T ^e   Yang, Haichen ^f   Li, David ^f   Barbato, Luigi M ^e,f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d ROGERS MEMORIAL HOSPITAL   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AEROLATE; CARTIA XT; CLOMIPRAMINE; DIGOXIN; DILTIAZEM; FLUOXETINE; FLUVOXAMINE MALEATE; PAROXETINE; PLACEBO; PROPRANOLOL; SERTRALINE; THEOPHYLLINE; WARFARIN;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; FEMALE; HUMAN; IMPOTENCE; INFECTION; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REMISSION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

EID: 0037929415     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0604     Document Type: Article

References (36)

1. Hollander E, Stein DJ, Kwon JH, et al. Psychosocial function and economic costs of obsessive-compulsive disorder. CNS Spectrums 1997;2:16-25
2. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am 2000;23:509-517
3. Goodman WK. Obsessive-compulsive disorder: diagnosis and treatment. J Clin Psychiatry 1999;60(suppl 18):27-32
4. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(suppl 14):39-45
5. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
6. Goodman WK, Ward H, Kablinger A, et al. Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. J Clin Psychiatry 1997;58(suppl 5):32-49
7. Flament MF, Bisserbe J-C. Pharmacologic treatment of obsessive-compulsive disorder: comparative studies. J Clin Psychiatry 1997;58 (suppl 12):18-22
8. Mundo E, Bianchi L, Bellodi L. Efficacy of fluvoxamine, paroxefine, and citalopram in the treatment of obsessive-compulsive disorder: a single blind study. J Clin Psychopharmacol 1997;17:267-271
9. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-29
10. Greist JH, Jenike MA, Robinson D, et al. Efficacy of fluvoxamine in obsessive-compulsive disorder: results of a multicentre, double-blind placebo-controlled trial. Eur J Clin Res 1995;7:195-204
11. Tollefson GD, Rampey AH, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
12. Zohar J, Judge R, and the OCD Paroxefine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996;169:468-474
13. Greist J, Chouinard G, Duboff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
14. Freeman CPL, Trimble MR, Deakin JFW, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994;55:301-305
15. Bisserbe JC, Lane R, Flament MF. Double-blind comparison of sertraline and clomipramine in patients with obsessive-compulsive disorder. Eur Psychiatry 1997;12:82-93
16. Koran LM, McElroy SL, Davidson JR, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996;16:121-129
17. Tamimi RR, Mavissakalian MR, Jones B, et al. Clomipramine versus fluvoxamine in obsessive-compulsive disorder. Ann Clin Psychiatry 1991;3:275-279
18. O'Connor K, Todorov C, Robillard S, et al. Cognitive-behaviour therapy and medication in the treatment of obsessive-compulsive disorder: a controlled study. Can J Psychiatry 1999;44:64-70
19. Hollander E, Allen A, Steiner M, et al. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J Clin Psychiatry. In press
20. Hollander E, Pallanti S. Current and experimental therapeutics of obsessive-compulsive disorder. In: Davis KL, Charney D, Coyle JT, et al, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, Pa: Lippincott Williams & Wilkins; 2002:1647-1664
21. Koran LM, Sallee FR, Pallanti S. Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 1997;144:396-401
22. Bogetto F, Albert U, Maina G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur Neuropsychopharmacol 2002;12:181-186
23. Stein MB, Fyer AJ, Davidson JR, et al. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999;156:756-760
24. van Megen HJ, Westenberg HG, den Boer JA, et al. Effect of the selecfive serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl) 1997;129:357-364
25. Bakish D, Hooper CL, Filteau MJ, et al. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia. Psychopharmacol Bull 1996;32:135-141
26. De Boer M, Op den Velde W, Falger PJ, et al. Fluvoxamine treatment for chronic PTSD: a pilot study. Psychother Psychosom 1992;57:158-163
27. Remick RA, Reesal R, Oakander M, et al. Comparison of fluvoxamine and amitriptyline in depressed outpatients. Curr Ther Res 1994;55:243-250
28. Feighner JP, Boyer WF, Meredith CH, et al. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. Int Clin Psychopharmacol 1989;4:239-244
29. Conti L, Dell'Osso L, Re F, et al. Fluvoxamine maleate: double-blind clinical trial versus placebo in hospitalized depressed patients. Curr Ther Res 1988;43:468-480
30. Dominguez RA, Goldstein BJ, Jacobson AF, et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. J Clin Psychiatry 1985;46:84-87
31. Amin MM, Ananth JV, Coleman BS, et al. Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study. Clin Neuropharmacol 1984;7(suppl 1):580-581
32. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011
33. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
34. First MB, Spitzer RL, Gibbon M, et al. Structured Clinical Interview for DSM-IV. New York, NY: Biometric Research, New York State Psychiatric Institute; 1995
35. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
36. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738